Don Davis’s Life Science Success podcast

17 September 2024

Angiex CEO Paul Jaminet Discusses Breakthrough Cancer Therapies on Life Science Success Podcast

In a recent episode of the Life Science Success podcast, Paul Jaminet, CEO of Angiex, shared insights into the company’s groundbreaking work on TM4SF1-targeted antibody-drug conjugates (ADCs) aimed at treating aggressive cancers. Jaminet highlighted Angiex’s innovative focus on targeting tumor blood vessels, offering a unique approach to combatting cancer. He also discussed the challenges in developing first-in-class therapies and the opportunities that lie ahead for Angiex as it progresses through clinical trials.

Life Science Success is hosted by Don Davis, PhD, a seasoned life-sciences executive with deep experience in guiding companies through growth and operational excellence. Dr. Davis has worked extensively in leadership, consulting, and strategic roles across the biotech and pharmaceutical sectors, making him an insightful interviewer for cutting-edge topics. His podcast features industry leaders discussing innovation, growth strategies, and the future of life sciences.

This episode provides listeners with an inside look at Angiex’s mission and its potential to revolutionize cancer treatment through targeted therapies. The Life Science Success podcast offers a platform for biotech and pharma professionals to explore key industry trends, and this episode underscores the critical role of companies like Angiex in shaping the future of cancer care.


About Angiex

Angiex Inc. is a privately held biotech startup whose mission is to exploit newly discovered biological transport mechanisms to make drugs with revolutionary power over cancer. Based in Cambridge, Mass., Angiex was founded by a scientific team of leading experts in angiogenesis, vascular biology, and oncology. The company is developing a novel portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) that release therapeutic payloads directly into the nucleus or cytosol, where the site of payload action is located. This direct delivery holds the promise of enhancing the efficacy and therapeutic margin of conventional ADCs. The lead product, AGX101, has advanced through pre-clinical development and is about to begin Phase 1 clinical trials. To learn more about Angiex...